The Long Game: A Functional Cure Is Possible with Nucleoside Analogues and the Tincture of Time
Abstract
:1. Introduction
2. Case Series
3. Discussion and Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- El-Serag, H.B. Hepatocellular carcinoma: Recent trends in the United States. Gastroenterology 2004, 127, S27–S34. [Google Scholar] [CrossRef] [PubMed]
- Perz, J.F.; Armstrong, G.L.; Farrington, L.A.; Hutin, Y.J.; Bell, B.P. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol. 2006, 45, 529–538. [Google Scholar] [CrossRef] [PubMed]
- Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69–90. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nassal, M. HBV cccDNA: Viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut 2015, 64, 1972–1984. [Google Scholar] [CrossRef] [Green Version]
- Spyrou, E.; Smith, C.I.; Ghany, M.G. Hepatitis B: Current status of therapy and future therapies. Gastroenterol. Clin. 2020, 49, 215–238. [Google Scholar] [CrossRef]
- Fung, S.; Choi, H.S.J.; Gehring, A.; Janssen, H.L.A. Getting to HBV cure: The promising paths forward. Hepatology 2022, 76, 233–250. [Google Scholar] [CrossRef]
- Martinez, M.G.; Testoni, B.; Zoulim, F. Biological basis for functional cure of chronic hepatitis B. J. Viral Hepat. 2019, 26, 786–794. [Google Scholar] [CrossRef]
- Martinez, M.G.; Villeret, F.; Testoni, B.; Zoulim, F. Can we cure hepatitis B virus with novel direct-acting antivirals? Liver Int. 2020, 26, 27–34. [Google Scholar] [CrossRef] [Green Version]
- Liang, T.J.; Block, T.M.; McMahon, B.J.; Ghany, M.G.; Urban, S.; Guo, J.; Locarnini, S.; Zoulim, F.; Chang, K.; Lok, A.S. Present and future therapies of hepatitis B: From discovery to cure. Hepatology 2015, 62, 1893–1908. [Google Scholar] [CrossRef] [Green Version]
- Feldman, M.; Friedman, L.S.; Brandt, L.J.; Hepatitis, B. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease: Pathophysiology; Elsevier: Philadelphia, PA, USA, 2021. [Google Scholar]
- Moini, M.; Fung, S. HBsAg loss as a treatment endpoint for chronic HBV infection: HBV cure. Viruses 2022, 14, 657. [Google Scholar] [CrossRef]
- Hsu, Y.-C.; Yeh, M.-L.; Wong, G.L.-H.; Chen, C.-H.; Peng, C.-Y.; Buti, M.; Enomoto, M.; Xie, Q.; Trinh, H.; Preda, C.; et al. Incidences and determinants of functional cure during entecavir or tenofovir disoproxil fumarate for chronic hepatitis B. J. Infect. Dis. 2021, 224, 1890–1899. [Google Scholar] [CrossRef] [PubMed]
- Papatheodoridi, M.; Papatheodoridis, G.V. State-of-the-art and emerging antivirals for chronic hepatitis B infection. Expert Opin. Pharm. 2022, 23, 1999–2012. [Google Scholar] [CrossRef]
- Chang, M.L.; Liaw, Y.F. Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure. Drugs 2023, 83, 367–388. [Google Scholar] [CrossRef] [PubMed]
- Shinn, B.; Cao, C.; Roth, C.; Brown, N.; Hann, H.W. Lamivudine Revisited: Long-Term Treatment of Relatively Low-Viremic Hepatitis B Patients on Higher-Dose Lamivudine. Med. Clin. Res. 2020, 5, 305–310. [Google Scholar]
- Chae, H.B.; Hann, H.-W. Baseline HBV DNA level is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine. World J. Gastroenterol. 2007, 13, 4085. [Google Scholar] [CrossRef] [Green Version]
- Liaw, Y.-F.; Kao, J.-H.; Piratvisuth, T.; Chan, H.L.Y.; Chien, R.-N.; Liu, C.-J.; Gane, E.; Locarnini, S.; Lim, S.-G.; Han, K.-H.; et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2012 update. Hepatol. Int. 2012, 6, 531–561. [Google Scholar] [CrossRef] [Green Version]
- Medas, R.; Liberal, R.; Macedo, G. Discontinuation of antiviral therapy in chronic hepatitis B patients. World J. Clin. Cases 2021, 9, 6979. [Google Scholar] [CrossRef]
- Broquetas, T.; Carrión, J.A. Current Perspectives on Nucleos(t)ide Analogue Therapy for the Long-Term Treatment of Hepatitis B Virus. Hepatic Med. Evid. Res. 2022, 14, 87–100. [Google Scholar] [CrossRef]
- Zhang, Q.; Liu, X.; Pang, X.; Wang, H.; Du, J.; Ren, H.; Hu, P. Recovery of host adaptive immune function promoted the reduction of hepatitis B surface antigen in nucleoside analog-experienced chronic hepatitis B patients with low hepatitis B surface antigen levels. Cytokine 2023, 164, 156140. [Google Scholar] [CrossRef]
- Hirode, G.; Choi, H.S.; Chen, C.H.; Su, T.H.; Seto, W.K.; Van Hees, S.; Papatheodoridi, M.; Lens, S.; Wong, G.; Brakenhoff, S.M.; et al. Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: An international, multicenter, multiethnic cohort (RETRACT-B study). Gastroenterology 2022, 162, 757–771. [Google Scholar] [CrossRef]
- Zeisel, M.B.; Lucifora, J.; Mason, W.S.; Sureau, C.; Beck, J.; Levrero, M.; Kann, M.; A Knolle, P.; Benkirane, M.; Durantel, D.; et al. Towards an HBV cure: State-of-the-art and unresolved questions—Report of the ANRS workshop on HBV cure. Gut 2015, 64, 1314–1326. [Google Scholar] [CrossRef] [PubMed]
- Zoulim, F.; Lebosse, F.; Levrero, M. Current treatments for chronic hepatitis B virus infections. Curr. Opin. Virol. 2016, 18, 109–116. [Google Scholar] [CrossRef] [PubMed]
- Levrero, M.; Testoni, B.; Zoulim, F. HBV cure: Why, how, when? Curr. Opin. Virol. 2016, 18, 135–143. [Google Scholar] [CrossRef] [PubMed]
HBsAg | Anti-HBs | Viremia | cccDNA | |
---|---|---|---|---|
Functional Cure | - | + | - | + |
Complete Cure | - | + | - | - |
Patient | Current Age | Sex | Age at Dx | Maternal or Paternal Family History (HBV) |
---|---|---|---|---|
1 | 44 | M | 12 | Maternal |
2 | 48 | F | 12 | Unknown |
3 | 54 | M | 33 | None |
4 | 74 | F | 36 | None |
5 | 66 | M | 42 | Unknown |
6 | 66 | M | 34 | None |
7 | 72 | F | 46 | None |
8 | 78 | F | 44 | Both |
9 | 59 | M | 29 | Maternal |
10 | 65 | M | 40 | None |
11 | 61 | M | 16 | Maternal |
12 | 66 | M | 43 | Unknown |
13 | 69 | F | 30 | Maternal |
14 | 58 | F | 33 | Maternal |
15 | 51 | M | 19 | Maternal |
16 | 56 | M | 23 | Maternal |
17 | 52 | M | 32 | Paternal |
18 | 61 | M | 16 | Maternal |
19 | 69 | M | 63 | None |
20 | 18 | M | 15 | Maternal |
Patient (Current Age) | Years of HBsAg+ | Time between DNA- and HBsAg Loss | Treatment (Year Began) | Length of Treatment (Years) | Time HBsAg- from Cessation of Treatment (Years) |
---|---|---|---|---|---|
1 (44 years) | 30 | 10 months | None | n/a | n/a |
2 (48 years) | 20 | 4 years | None | n/a | n/a |
3 (54 years) | 10 | 3 years 3 months | LAM (2004), TDF (2009) | 8 | 10 |
4 (74 years) | 35 | 2 years 3 months | LAM (2004), TDF (2011), TAF (2017) | 14 | 1 |
5 (66 years) | 20 | 9 years 4 months | TLB (2008), ETV (2008), TAF (n/a), TDF (n/a) | 18 | 1 |
6 (66 years) | 20 | 3 years 7 months | IFN (n/a) LAM (n/a), TDF (n/a), ADV (n/a) | 20 | 13 |
7 (72 years) | 22 | 18 years | LAM (2003), TDF (2016) | 19 | 1 |
8 (78 years) | 22 | 5 years | LAM (2002) | 3 | 14 |
9 (59 years) | 30 | 11 years | LAM (2000), TDF (2011) | 30 | 1 |
10 (65 years) | 25 | 14 years | LAM (2002), ADV (2008), TDF (2017), LAM (2020), TDF (2020) | 19 | 1 |
11 (61 years) | 45 | 9 years | LAM (2009), REALM ETV (2009) | 13 | 1 |
12 (66 years) | 23 | 10 years | TDF (2012), LAM | 10 | 1 |
13 (69 years) | 39 | 13 years | LAM (2009) | 19 | 1 |
14 (58 years) | 24 | 1 year 6 months | LAM (n/a), ADV (n/a), TDF (n/a) | 12 | 1 |
15 (51 years) | 32 | 12 years | LAM (2009), TLB (2009), TDF (2009), TAF (2018) | 18 | 1 |
16 (56 years) | 33 | 17 years | LAM (1999), LAM (2002), LAM-r (2003), TDF (2004), TAF (2021) | 23 | 1 |
17 (52 years) | 20 | 15 years | LAM (2006), TDF (2021) | 12 | 1 |
18 (61 years) | 45 | 10 years 4 months | LAM (2006), RTV, TAF (n/a), ETV (n/a) | 16 | 1 |
19 (69 years) | n/a | 5 years | TDF (n/a), TAF (n/a) | 6 | 1 |
20 (18 years) | 3 | 2 years | None | n/a | n/a |
Patient (Current Age) | Details of Family History |
---|---|
1 (44 years) | Mother and older brother are HBsAg (+) but are not on anti-HBV therapy. |
2 (48 years) | Unknown |
3 (54 years) | Unknown |
4 (74 years) | Unknown |
5 (66 years) | Younger brother has CHB and is on therapy. |
6 (66 years) | Unknown |
7 (72 years) | Older brother has HCC. Maternal uncle has CHB and is on therapy. |
8 (78 years) | Mother and father have cirrhosis. Younger brother and sister have CHB and are on therapy. |
9 (59 years) | Mother, older brother, and sister and younger brother are HBsAg (+) and is not on therapy. |
10 (65 years) | Unknown |
11 (61 years) | Older brother has HCC. Mother has cirrhosis. Older brother has CHB and is on therapy. |
12 (66 years) | Unknown |
13 (69 years) | Mother and older brother have HCC. Older sister has cirrhosis. Two older brothers and three older sisters have CHB and are on therapy. |
14 (58 years) | One older brother, one older sister, and one younger brother are HBsAg (+) and are not on anti-HBV therapy. |
15 (51 years) | Two maternal aunts have HCC. One younger sister, one younger brother, and three maternal aunts all have CHB and are on therapy. |
16 (56 years) | Father, younger brother, and sister have HBsAg (+) and are not on therapy. |
17 (52 years) | Unknown |
18 (51 years) | Unknown |
19 (69 years) | Unknown |
20 (18 years) | Mother and two sisters are HBsAg (+). |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Noverati, N.; Yan, V.; Jun, J.W.; Halegoua-DeMarzio, D.; Hann, H.-W. The Long Game: A Functional Cure Is Possible with Nucleoside Analogues and the Tincture of Time. Livers 2023, 3, 325-330. https://0-doi-org.brum.beds.ac.uk/10.3390/livers3030024
Noverati N, Yan V, Jun JW, Halegoua-DeMarzio D, Hann H-W. The Long Game: A Functional Cure Is Possible with Nucleoside Analogues and the Tincture of Time. Livers. 2023; 3(3):325-330. https://0-doi-org.brum.beds.ac.uk/10.3390/livers3030024
Chicago/Turabian StyleNoverati, Nicholas, Vivian Yan, Jay W. Jun, Dina Halegoua-DeMarzio, and Hie-Won Hann. 2023. "The Long Game: A Functional Cure Is Possible with Nucleoside Analogues and the Tincture of Time" Livers 3, no. 3: 325-330. https://0-doi-org.brum.beds.ac.uk/10.3390/livers3030024